

	No Zoledronic Acid (N = 59)	Zoledronic Acid (N = 60)
Deceased, N (%)	23 (38.9)	27 (45)
Follow-Up > 13 years, N (%)	29 (49.2)	23 (38.3)
Follow-Up 10-13 years, N (%)	6 (10.2)	4 (6.7)
Follow-Up 5-10 years, N (%)	1 (1.7)	3 (5)
Follow-Up < 5 years, N (%)	0	3 (5)

Table S1 Length of patient follow-up




Fig. S1 Effect of ZOL treatment on TTR (A), TTBR (B), TTNBR (C), BCS (D) and OS (E) in patients 45 years of age and older




Fig. S2 Effect of ZOL treatment on TTR (A), TTBR (B), TTNBR (C), BCS (D) and OS (E) in patients age 45-54




Fig. S3 Effect of ZOL treatment on TTR (A), TTBR (B), TTNBR (C), BCS (D) and OS (E) in ER+/HER2- patients 45 years of age and older




Fig. S4 Effect of ZOL treatment on TTR (A), TTBR (B), TTNBR (C), BCS (D) and OS (E) in triple-negative patients younger than 45




Fig. S5 Effect of ZOL treatment on TTR (A), TTBR (B), TTNBR (C), BCS (D) and OS (E) in triple-negative patients 45 years of age and older

	TAM (%)	AI (%)	OS + TAM (%)	OS + AI (%)	Unknown (%)
Age < 45					
No ZOL (N = 14)	7 (50)	3 (21.4)	4 (28.6)	0	0
ZOL (N = 8)	4 (50)	2 (25)	1 (12.5)	0	1 (12.5)
Age >= 45					
No ZOL (N = 15)	4 (26.7)	9 (60)	0	0	2 (13.3)
ZOL (N = 18)	4 (22.2)	11 (61.1)	1 (5.6)	1 (5.6)	1 (5.6)

TAM = tamoxifen, AI = aromatase inhibitor, OS = ovarian suppression

Table S2 Endocrine therapy in ER+/HER2- patients